Immunotherapy + Electroporation for Pancreatic Cancer

"Currently, 82 trials for Nivolumab are in the third phase of research and development, out of a total 718 active studies. Most trials for this drug take place in Basel, BE; however there are 40237 sites offering clinical testing worldwide."

"Presently, 718 active studies on Nivolumab have been organized in 2354 cities and 49 nations. This medication was first tested for efficacy back in 2012 by Ono Pharmaceutical Co. Ltd with a Phase 1 & 2 trial involving 659 patients. Since then, 255 additional trials have concluded."

"Unfortunately, no more patients are being sought for this trial. It was first introduced on the 14th of August 2017 and most recently updated on October 24th 2022. For those looking to join an ongoing study, 787 clinical trials with adenocarcinoma as a focus and 718 studies involving Nivolumab remain in search of participants."

"Nivolumab is suitable for the management of many malignant neoplasms, ranging from inoperable melanomas to metastatic esophageal adenocarcinoma and squamous cell carcinoma."

"Considering the phase of this trial, there is enough evidence to suggest Nivolumab's safety merits a score of 2. Unfortunately, no trials have been conducted to confirm its efficacy as yet."

"As per the information on clinicaltrials.gov, this study has finished recruiting participants. The trial was initially posted in August 2017 and last updated in October 2022. Nevertheless, at present there are 1,505 other medical studies actively seeking volunteers."